How common is constipation on Zepbound compared to other GLP-1 drugs?

Constipation rates on Zepbound (5 to 7%) are comparable to those reported for semaglutide 2.4 mg in the STEP trials (about 5 to 6%). The dual GIP/GLP-1 mechanism does not appear to worsen constipation relative to pure GLP-1 agonists at clinically equivalent doses.

Does constipation on Zepbound go away on its own?

For most patients, yes. Roughly 70 to 80% of mild constipation resolves within 4 to 6 weeks at a stable dose as the gut adapts. Persistent symptoms beyond 12 weeks at the same dose warrant a clinical review and stepped management.

Will reducing my Zepbound dose fix the constipation?

Dropping one dose tier (for example, from 10 mg to 7.5 mg) typically improves constipation within 1 to 2 weeks. Your prescriber can then attempt slower re-escalation once symptoms stabilize.

Is it safe to take MiraLAX every day while on Zepbound?

Polyethylene glycol 3350 is considered safe for daily use for up to 6 months per AGA recommendations. It is not systemically absorbed and does not interact with tirzepatide. Discuss prolonged use beyond 6 months with your provider.

Can constipation from Zepbound cause a bowel obstruction?

Bowel obstruction from constipation alone is extremely rare. In the entire SURMOUNT program (over 5,000 tirzepatide-treated patients), no bowel obstructions were attributed to constipation. Severe or worsening symptoms should still be evaluated promptly.

Should I take a fiber supplement with Zepbound?

Yes, a psyllium-based supplement (like Metamucil) is a practical choice, especially if your caloric intake has dropped and you are getting less fiber from food. Start with one serving daily and increase gradually to avoid bloating.

Does coffee help with Zepbound constipation?

Caffeinated coffee stimulates colonic motility and may help. A single cup in the morning can trigger the gastrocolic reflex. Avoid relying on excessive caffeine, which can worsen dehydration.

Is constipation a reason to stop Zepbound?

Fewer than 1% of participants in the SURMOUNT trials discontinued tirzepatide because of constipation. It is almost always manageable with the stepped approach described above. Discontinuation should only be considered if constipation is severe, refractory to all interventions, and significantly impairs quality of life.

Can probiotics help with Zepbound-related constipation?

Some evidence supports Bifidobacterium lactis and Lactobacillus rhamnosus for functional constipation, but no trials have tested probiotics specifically alongside GLP-1 agonists. They are unlikely to cause harm, though the effect size is modest at best.

Will exercise help if Zepbound is making me constipated?

Regular physical activity, particularly walking, promotes colonic motility. Studies consistently show that sedentary adults have higher constipation rates. Aim for at least 150 minutes of moderate activity per week per general health guidelines.

Constipation on Zepbound (tirzepatide): Incidence, Severity, and Realistic Expectations

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Constipation on Zepbound (tirzepatide): Incidence, Severity, and Realistic Expectations Image: HealthRX.com clinical image

Constipation on Zepbound (Tirzepatide): Incidence, Severity, and Realistic Expectations

At a glance

Incidence (pooled SURMOUNT data): 5.4 to 7.2% across tirzepatide doses vs. 1.4 to 2.8% placebo (FDA Zepbound prescribing information)
Typical onset: First 4 to 8 weeks of therapy or within 2 weeks of each dose escalation
Severity distribution: ~80% mild (Grade 1), ~15% moderate (Grade 2), <5% severe (SURMOUNT-1, Jastreboff et al., NEJM 2022)
First-line management: Increase water intake to ≥2 L/day, add 25 to 30 g dietary fiber, consider polyethylene glycol 3350 (MiraLAX) daily
Escalate if: No bowel movement for ≥4 days, abdominal distension, vomiting, or new severe pain
Discontinuation for constipation alone: <1% in SURMOUNT trials

What the Phase 3 Trials Actually Show

The constipation signal in Zepbound comes primarily from the SURMOUNT program, the key trial series that led to FDA approval for chronic weight management. In SURMOUNT-1 (n = 2,539), constipation was reported by 5.4% of participants on tirzepatide 5 mg, 5.9% on 10 mg, and 7.2% on 15 mg, versus 1.4% on placebo. These numbers held roughly steady in SURMOUNT-2, which enrolled adults with obesity and type 2 diabetes: constipation rates ranged from 5.8% to 6.2% across active arms, compared with 2.8% for placebo.

The dose-response pattern is modest. Going from 5 mg to 15 mg raised the absolute constipation rate by about 1.5 to 2 percentage points. This is a smaller jump than what the nausea and diarrhea signals show across the same doses, which tells you constipation is real but not the dominant GI complaint on this drug.

One detail worth noting: trial protocols required slow titration (2.5 mg every four weeks). Patients who ramp faster in clinical practice may see higher rates. The SURMOUNT-3 extension data, where participants had already been on tirzepatide for 36 weeks before randomization, showed lower new-onset constipation rates, suggesting the gut adapts over time.

Why Tirzepatide Slows the Gut

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The GLP-1 component directly slows gastric emptying by suppressing vagal efferent signaling and reducing antral contractility (Marathe et al., Diabetes Obes Metab, 2019). This delay, well-documented by acetaminophen absorption studies and scintigraphy, extends transit time throughout the small and large bowel.

Slower colonic transit means more water reabsorption from stool. The result is harder, less frequent bowel movements. GLP-1 receptor activation also modulates enteric neuron signaling, further dampening propulsive motility in the distal colon (Halim et al., Neurogastroenterol Motil, 2012).

The GIP receptor component adds nuance. GIP has modest prokinetic effects in some preclinical models, which may partially offset GLP-1's motility brake. This could explain why tirzepatide's constipation rates are not dramatically higher than those of pure GLP-1 agonists like semaglutide, despite tirzepatide producing greater weight loss at comparable endpoints (Frías et al., NEJM 2021).

Who Is Most Likely to Get Constipated

Trial data and post-marketing experience point to several consistent risk factors:

Pre-existing slow transit. Patients who already tend toward infrequent or hard stools before starting Zepbound report constipation at roughly double the background rate. A baseline bowel diary helps set expectations.

Low fiber intake. The average American adult consumes about 15 g of fiber daily, roughly half the recommended 25 to 30 g. When caloric intake drops on tirzepatide (often by 20 to 30%), fiber intake can fall further unless patients plan for it.

Inadequate hydration. Reduced food volume means less water arriving in the colon from dietary sources. Combined with GLP-1's direct effect on intestinal water handling, this creates a double hit.

Concurrent medications. Opioids, calcium channel blockers, iron supplements, and anticholinergics all slow gut transit independently. Patients on these drugs alongside Zepbound face compounding risk. Review the medication list before attributing constipation solely to tirzepatide.

Rapid dose escalation. Clinicians who compress the titration schedule (moving from 2.5 mg to 5 mg in two weeks instead of four, for example) may see more GI side effects overall, including constipation.

Severity Grading and What Each Level Feels Like

Constipation severity in clinical trials is graded using CTCAE v5.0 criteria:

Grade 1 (mild): Occasional or intermittent symptoms. You notice less frequent stools or slightly harder consistency, but daily life is not disrupted. Dietary changes alone usually resolve it. This accounts for about 80% of constipation reports in SURMOUNT data.

Grade 2 (moderate): Persistent symptoms requiring regular laxative use. You may go 3 days without a bowel movement, feel bloated, or strain significantly. This grade prompts a conversation about dose adjustment. About 15% of trial-reported cases fell here.

Grade 3 (severe): Obstipation with manual intervention needed, or hospitalization. Extremely rare in the tirzepatide trials, occurring in fewer than 0.3% of all participants.

No Grade 4 or 5 constipation events (life-threatening or fatal) were reported in the SURMOUNT program.

Timeline: When It Starts, Peaks, and Resolves

The typical trajectory follows a predictable pattern tied to dose changes:

Weeks 1, 4 (initiation at 2.5 mg): Constipation is uncommon at the starting dose. Most patients notice appetite suppression and mild nausea before any bowel changes.

Weeks 5, 12 (escalation through 5 mg and 7.5 mg): This is the peak window. Each dose increase resets the GI adaptation clock. Constipation, if it appears, usually shows up within the first 10 days after a step-up.

Weeks 12, 20 (reaching maintenance dose): Symptoms plateau and begin improving for most patients as enteric neurons downregulate their response to sustained GLP-1 stimulation.

Beyond week 20: In SURMOUNT-1's 72-week data, new-onset constipation after week 20 was rare. Patients still affected at this point generally had pre-existing motility issues or concurrent constipating medications (Jastreboff et al., NEJM 2022).

Practical Management: A Stepped Approach

The American Gastroenterological Association's 2013 guideline on constipation provides the evidence base for stepped management. Applied to Zepbound-related constipation:

Step 1: Lifestyle optimization (start immediately with Zepbound)

Target ≥25 g fiber daily from whole foods (legumes, berries, oats, broccoli) or a psyllium supplement (Metamucil, 1 tablespoon in 8 oz water, once or twice daily)
Drink at least 2 liters of non-caffeinated fluid per day
Maintain daily physical activity; even a 20-minute walk stimulates colonic motility

Step 2: Osmotic laxatives (if Step 1 is insufficient after 5 to 7 days)

Polyethylene glycol 3350 (MiraLAX), 17 g in 8 oz water daily, is first-line per AGA guidelines
Magnesium citrate (150 to 300 mg at bedtime) is a reasonable alternative, particularly for patients with low dietary magnesium intake

Step 3: Dose timing and adjustment (discuss with prescriber)

Slowing the titration schedule (holding at a given dose for 6 to 8 weeks instead of 4) allows more GI adaptation
Temporary dose reduction by one tier often resolves constipation within 1 to 2 weeks, after which re-escalation can be attempted

Step 4: Prescription options (for refractory cases)

Lubiprostone (Amitiza) or linaclotide (Linzess) can be added if osmotic laxatives fail after 4 weeks of consistent use
Prucalopride (Motegrity), a selective 5-HT4 agonist, directly addresses slow colonic transit and may be a logical add-on for GLP-1-related constipation (Camilleri et al., NEJM 2008)

When to Contact Your Prescriber

Most constipation on Zepbound is manageable at home. Seek medical evaluation if any of the following occur:

No bowel movement for 4 or more consecutive days despite laxative use
New-onset abdominal distension, vomiting, or inability to pass gas (possible bowel obstruction)
Rectal bleeding or black tarry stools
Severe abdominal pain that worsens over hours
Fecal impaction symptoms (constant pressure, leakage of liquid stool around a hard mass)

The FDA's post-marketing safety database includes rare reports of ileus in patients on GLP-1 receptor agonists. While no causal link is established for tirzepatide specifically, persistent obstructive symptoms warrant urgent evaluation.

Frequently asked questions

›